

REVIEW

Use of Cannabidiol for the Treatment of Anxiety: A Short Synthesis of Pre-Clinical and Clinical Evidence

Madison Wright,^{1,2} Patricia Di Ciano,^{1-3,*} and Bruna Brands^{1,2,4}

Abstract

Anxiety disorders have the highest lifetime prevalence of any mental illness worldwide, leading to high societal costs and economic burden. Current pharmacotherapies for anxiety disorders are associated with adverse effects and low efficacy. Cannabidiol (CBD) is a constituent of the *Cannabis* plant, which has potential therapeutic properties for various indications. After the recent legalization of cannabis, CBD has drawn increased attention as a potential treatment, as the majority of existing data suggest it is safe, well tolerated, has few adverse effects, and demonstrates no potential for abuse or dependence in humans. Pre-clinical research using animal models of innate fear and anxiety-like behaviors have found anxiolytic, antistress, anticomulsive, and panicolytic-like effects of CBD. Preliminary evidence from human trials using both healthy volunteers and individuals with social anxiety disorder, suggests that CBD may have anxiolytic effects. Although these findings are promising, future research is warranted to determine the efficacy of CBD in other anxiety disorders, establish appropriate doses, and determine its long-term efficacy. The majority of pre-clinical and clinical research has been conducted using males only. Among individuals with anxiety disorders, the prevalence rates, symptomology, and treatment response differ between males and females. Thus, future research should focus on this area due to the lack of research in females and the knowledge gap on sex and gender differences in the effectiveness of CBD as a potential treatment for anxiety.

Keywords: cannabinoids; cannabis; CBD; clinical trials; mental illness

Introduction

Anxiety disorders are the most prevalent mental illnesses in the world, leading to high societal costs and economic burden.¹ Anxiety is characterized by excessive anticipation of future threats and accompanied by excessive fear, which is an emotional response to imminent threats.² Persistent fear and anxiety lead to maladaptive behavioral disturbances and disability. Anxiety disorders are associated with panic attacks, avoidance behavior, and diminished sense of well-being, leading to troubled relationships, increased rates of unemployment, and elevated risk of suicide.³ Neuropsychiatric anxiety disorders include generalized anxiety disorder (GAD), social anxiety disorder (SAD; also known as social phobia), specific phobia, panic disorder, and agora-

phobia.² Obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are no longer classified as anxiety disorders in the Diagnostic and Statistical Manual of Mental Disorders-5²; however, they both encompass excessive anxiety and share common symptomology with anxiety disorders.³ These disorders tend to be chronic and persistent, lasting 6 months or more, and have high comorbidity rates with other anxiety disorders and mental illnesses.^{2,4}

Currently, the main pharmacological treatments for anxiety disorders include selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, tricyclics, partial 5-hydroxytryptamine 1A (5-HT_{1A}) receptor agonists, and benzodiazepines.⁵ These pharmacotherapies tend

¹Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Canada.

²Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada.

³Campbell Family Mental Health Research Institute, Toronto, Canada.

⁴Controlled Substances and Cannabis Directorate, Health Canada, Ottawa, Canada.

*Address correspondence to: Patricia Di Ciano, PhD, Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, 33 Russell Street, Toronto, M5S 2S1, Canada, E-mail: patricia.diciano@camh.ca

to have adverse effects and low efficacy (in only about 40–60% of patients),⁴ with the majority of patients failing to achieve complete remission.⁶ Anxiety disorders may additionally be treated using psychological approaches, including cognitive behavioral therapy, exposure therapy, and cognitive processing therapy,⁴ although these therapies tend to be costly and limited to some therapeutic contexts.⁷ Thus, there is a strong and urgent need to develop novel treatment approaches for anxiety disorders.

Cannabidiol (CBD) is a constituent of the *Cannabis* plant, which has potential therapeutic properties across many neuropsychiatric disorders.⁸ Indeed, Epidiolex[®] (99% CBD; 0.1% Δ -9-tetrahydrocannabinol [THC]) has been approved in some places for the treatment of epilepsy⁹ and clinical trials have established that CBD can be an effective treatment for pediatric epilepsy,^{10,11} or epilepsy with a pediatric onset.^{12,13} Interest in the broader therapeutic potential of CBD is exemplified by the burgeoning number of systematic reviews and meta-analyses published within the past few years that champion its use in a number of potential therapeutic indications. CBD is well tolerated and effective in studies of social anxiety during public speaking tasks,^{1,14,15} demonstrates promising data from early trials in psychosis to treat schizophrenia^{16,17} and in the early studies of motor and nonmotor symptoms of Parkinson's disease¹⁸; it has also shown some promise in colitis.¹⁹ Reviews of the pre-clinical literature have also shown some preliminary ability to ameliorate cancer tumors, alcohol use disorder,²⁰ pain,²¹ as well as acting as an anti-inflammatory, analgesic, antiarthritic, anti-Alzheimers, antidepressant, antidiabetic, as well as others.²²

The primary psychoactive component of cannabis, THC, has its actions primarily at the cannabinoid type 1 (CB1) receptor.²³ By comparison, the pharmacological profile of CBD is very different from THC and it is currently not fully understood.²³ Nevertheless, it is known to have interactions with several receptors in both the central and peripheral nervous systems,²⁴ which are known to regulate fear and anxiety. These receptors include the serotonin 5-HT1A receptor, the CB1 and CB2 receptors, and the transient receptor potential, vanilloid type 1 receptor (TRPV1).^{3,25} The acute anxiolytic effects of CBD at low and intermediate doses are thought to involve 5-HT1A activation.^{8,26} Whereas TRPV1 antagonism allows for the anxiolytic effects of higher CBD doses, the anxiogenic effects of higher CBD doses involves TRPV1 agonism.^{8,26} TRPV1 activity seems to be unique to CBD and a few

other minor cannabinoids, as THC does not interact with this receptor channel.²⁷

Another potential mechanism through which CBD produces anxiolytic effects is due to the action of the endogenous cannabinoid anandamide in the brain.²⁸ CBD has been shown to increase cannabinoid receptor activation indirectly by elevating endocannabinoid levels through its action on endocannabinoid metabolism.^{29,30} CBD has the ability to inhibit fatty acid amide hydrolase (FAAH) enzyme, which metabolizes anandamide, consequently enhancing anandamide levels and indirectly increasing CB1 receptor activation.²⁹ CB1 receptor activation has been thought to mediate the ability of CBD to regulate long-term learned fear processing.²⁵ Endocannabinoid signaling is part of an endogenous anxiolytic neuromodulatory system, thus inhibition of FAAH activity is a potentially promising therapeutic approach for reducing anxiety-related symptoms.³⁰

After the recent decriminalization and legalization of medical and recreational cannabis in certain countries and jurisdictions, cannabis use continues to increase.^{31–33} CBD has drawn increased attention as a potential treatment, as the majority of existing data suggest that it is safe, well tolerated, and has few adverse effects.³⁴ The World Health Organization stated that across a number of controlled open-label trials, CBD is generally well tolerated with a good safety profile.^{35–37} Several studies propose that CBD is nontoxic, does not induce changes in food intake or catalepsy, does not affect physiological measures, and does not alter psychomotor or psychological functions.³⁷ In addition, chronic use and high doses of up to 1500 mg/day are reportedly well tolerated in humans.³⁷

Thus far, CBD demonstrates no potential for abuse or dependence in humans.³⁸ In one study, it was found that subjective ratings of “stoned” did not increase after administration of CBD to participants.³⁹ In other studies, CBD had no effects on visual analog scales of drug “high,” “good drug effects,” “street value,”⁴⁰ “liking,” “take again,” “bad effects” or alertness/drowsiness; CBD had slight effects on ratings of the positive effects of the drug.⁴¹ THC alone or in combination with CBD increased ratings of “stoned,”³⁹ “high,” “good drug effect,” “liking,” “strength,” “good effect,” “desire to take again”⁴²; CBD thus had no effects on the subjective effects of THC. Although, it should be noted that in one study a high dose of vaporized CBD produced some intoxicating properties compared with placebo⁴³; therefore, CBD may have psychotropic properties in some preparations.

Pre-Clinical Studies

The anxiolytic effects of CBD were initially explored in pre-clinical studies, using several animal models and behavioral tests. The elevated plus-maze (EPM) was one of the first tests used in rodents to study the anxiolytic effects of CBD. Guimarães et al.⁴⁴ used the EPM to demonstrate a full dose–response curve in rats, after acute systemic administration of CBD, which produced a “bell-shaped” dose–response curve. These findings indicated that CBD is anxiolytic at low and intermediate doses and produces anxiogenic-like effects at higher doses. This has been further confirmed in other animal models of innate fear and anxiety-like behaviors using various behavioral tests, such as the EPM, open field, light–dark test, and predator exposure.²⁵ Furthermore, using the EPM, CBD displays anxiolytic effects similar to diazepam in both mice and rats.^{44,45} Other behavioral tests used include the Vogel test, classical conditioning, marble burying test, chronic unpredictable stress test, fear and predator exposure tests, and the social interaction test, which have demonstrated different findings, including anxiolytic, antistress, anticomulsive, and panicolytic-like effects in rodents (for recent reviews, see Blessing et al.,³ Lee et al.,⁸ and Papagianni and Stevenson²⁵).

To examine the mechanism of CBD-mediated anxiolytic-like effects in animals, microinjection models have been utilized. When CBD was injected into specific brain regions associated with anxiety, including the central nucleus of the amygdala, the dorsal periaqueductal gray, and the bed nucleus of the stria terminalis, anxiolytic effects were produced.³ Antagonism of the 5-HT_{1A} receptor resulted in attenuation of anxiolytic effects, thereby potentially mediated some symptoms of anxiety.²⁶ Overall, pre-clinical evidence strongly supports the anxiolytic role of CBD; however, the majority of pre-clinical research has only been conducted using male animals, therefore, these findings need to be replicated using females.^{3,8}

Clinical Studies

The anxiolytic effects of CBD observed in animals have provided insight and guided human research. The initial clinical studies examining the effects of CBD on anxiety were performed in the 1980s, when it was demonstrated that CBD could attenuate the anxiogenic and psychoactive effects of THC in healthy volunteers.^{46,47} Since then, studies in healthy volunteers^{14,46,48–50} and individuals with SAD^{15,28} provide early evidence that CBD may have anxiolytic effects in humans. The Sim-

ulation Public Speaking Test has been used to examine the effects of CBD on anxiety in clinical studies. In both healthy volunteers and individuals diagnosed with SAD, it was found that in comparison with the placebo group, a 400 or 600 mg single dose of CBD significantly reduced subjective symptoms of anxiety and decreased cognitive impairment and speech performance discomfort.^{15,28} Neuroimaging studies^{28,48,49,51,52} of acute administration of CBD have demonstrated modified blood flow in specific brain structures associated with anxiety, including the amygdala, hypothalamus, hippocampus, and cingulate cortex.⁵³ In addition, retrospective studies have found CBD to be effective in reducing anxiety symptoms in patients with anxiety disorders and PTSD. These studies examined varying doses (e.g., 25–75 mg/day) and preparations (e.g., oral, sublingual spray) of CBD across different patient populations and in combination with other forms of pharmacological and psychotherapies,^{54–56} although findings from such retrospective studies provide limited data due to small sample sizes and lack proper controls.

Three ongoing clinical trials are currently investigating the effects of CBD as a potential treatment for anxiety disorders.^{57–59} Van der Flier et al.⁵⁷ are examining the effects of a weekly dose of 300 mg of CBD administered orally for 8 weeks, in individuals with phobic disorders. An ongoing phase 3 clinical trial is exploring the use of 200 mg ranging up to 800 mg of CBD administered in oil capsules, for the treatment of GAD, SAD, panic disorder, and agoraphobia.⁵⁸ Finally, an open label phase 2 clinical trial is currently examining the effects of a sublingual, 1.0 mg CBD tincture (10 mg/mL of CBD) three times a day for 4 weeks, in patients with an anxiety disorder diagnosis.⁵⁹ These studies are of great importance because the majority of studies assessing the effects of CBD on anxiety were conducted in healthy volunteers, and the clinical trials involving patients with SAD used small sample sizes, did not include placebo controls and did not establish a dose–response relationship between CBD plasma levels and anxiety symptom measurements.⁶⁰ In addition, future clinical trials are warranted to examine the effects of CBD on other anxiety disorders, including GAD, panic disorder, and phobic disorder, as well as anxiety-related conditions, such as PTSD and OCD.

Sex Differences in Anxiety and the Utility of CBD

The prevalence rates of anxiety disorders are approximately doubled in females compared with males and

there are differing symptoms between sexes.^{2,61,62} After puberty, females are more prone to anxiety disorders compared with males, largely due to the involvement of sex chromosomes and hormones.^{63,64} Females typically demonstrate increased symptom severity, comorbidity, and burden of illness.⁶⁵ In terms of symptomology, females more frequently report somatic discomfort, demonstrate more internalizing coping styles, rumination, and have higher rates of comorbid mood disorders.^{61,66} Males are more likely to report strained relationships as a result of excessive worry, have an increased fear of social consequences, and are more likely to have comorbid alcohol and substance abuse.^{61,66} However, symptomology varies between different anxiety disorders, is influenced by social and environmental factors, and is dependent on puberty, menstrual cycle phase, pregnancy, and menopause in females.^{61,67} Males and females may respond differently to psychotropic medication^{67–69}; thus, it is important to understand sex differences in anxiety disorders to better develop treatments for both males and females.

It has been demonstrated in animals and humans that THC has differential effects in males and females.⁷⁰ Sex differences have been observed in the pharmacokinetics,^{71–74} pharmacodynamics,^{75–78} subjective effects,^{79–82} abuse liability,^{83–86} and therapeutic potential of THC (for recent review see Cooper and Craft⁷⁰). Thus, other agents that target the endocannabinoid system, such as CBD, might be expected to have similar sex-dependent effects. The pharmacokinetics of CBD differ between males and females^{71,87}; however, there are nearly no sex comparisons of its effects, even in animals.⁷⁰ The majority of current pre-clinical studies have solely been conducted using male animals,⁸ and to our knowledge no clinical studies have yet to explore sex and/or gender differences in CBD as a potential treatment for anxiety. Of the clinical studies that did include females,^{14,15,46} no sex-specific analyses were performed. Therefore, due to the increasing prevalence of anxiety disorders and lack of effectiveness of current treatments, it is crucial to conduct research studies examining sex and gender differences in use of CBD as a potential treatment for anxiety disorders.

Conclusions

Overall, existing pre-clinical and clinical evidence supports a possible role for CBD as a novel treatment for anxiety disorders. The findings reviewed in this

study demonstrate the potential of CBD to produce anxiolytic-like effects in pre-clinical models and the potential of CBD to induce acute anxiolytic effects when administered as a single dose in healthy volunteers and individuals with SAD. Although these findings are promising, future research is necessary to (1) determine the efficacy of CBD in other anxiety disorders aside from SAD in placebo-controlled clinical trials; (2) establish the most effective route of administration and appropriate dose of CBD to be utilized in treatment; and (3) determine the long-term safety and efficacy of CBD. There is a strong need to develop alternative and novel treatments for anxiety-related disorders, particularly focused on sex and gender differences, as prevalence rates, symptomology, and medication response differs between men and women. Owing to the lack of research in female animals and humans, and the knowledge gap on sex and gender differences in the effectiveness of CBD as a potential treatment for anxiety, future research should focus on this area.

Author Disclosure Statement

The authors declare that they do not have any competing interests.

Authors' Contributions

M.W. wrote the first draft of the article. P.D.C. and B.B. provided some text and modifications.

Funding Information

No funding was received for this article.

References

1. Scherma M, Masia P, Deidda M, et al. New perspectives on the use of cannabis in the treatment of psychiatric disorders. *Medicines (Basel)*. 2018;5:pii: E107.
2. American Psychological Association (APA). *Diagnostic and Statistical Manual of Mental Disorders (5th Edition)*. American Psychological Association: Washington, DC, 2013.
3. Blessing EM, Steenkamp MM, Manzanares J, et al. Cannabidiol as a potential treatment for anxiety disorders. *Neurotherapeutics*. 2015;12:825–836.
4. Craske MG, Stein MB, Eley TC, et al. Anxiety disorders. *Nat Rev Dis Primers*. 2017;3:17024.
5. Murrough JW, Yaqubi S, Sayed S, et al. Emerging drugs for the treatment of anxiety. *Expert Opin Emerg Drugs*. 2015;20:393–406.
6. Bandelow B, Sher L, Bunevicius R, et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. *Int J Psychiatry Clin Pract*. 2012;16:77–84.
7. Singewald N, Schmuckermair C, Whittle N, et al. Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders. *Pharmacol Ther*. 2015;149:150–190.
8. Lee JLC, Bertoglio LJ, Guimaraes FS, et al. Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders. *Br J Pharmacol*. 2017;174:3242–3256.

9. Billakota S, Devinsky O, Marsh E. Cannabinoid therapy in epilepsy. *Curr Opin Neurol*. 2019;32:220–226.
10. Elliott J, DeJean D, Clifford T, et al. Cannabis-based products for pediatric epilepsy: a systematic review. *Epilepsia*. 2019;60:6–19.
11. Lattanzi S, Brigo F, Trinka E, et al. Efficacy and safety of cannabidiol in epilepsy: a systematic review and meta-analysis. *Drugs*. 2018;78:1791–1804.
12. Stockings E, Zagic D, Campbell G, et al. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. *J Neurol Neurosurg Psychiatry*. 2018;89:741–753.
13. Zaheer S, Kumar D, Khan MT, et al. Epilepsy and cannabis: a literature review. *Cureus*. 2018;10:e3278.
14. Zuardi AW, Cosme RA, Graeff FG, et al. Effects of ipsapirone and cannabidiol on human experimental anxiety. *J Psychopharmacol*. 1993;7(1 Suppl.):82–88.
15. Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. *Neuropsychopharmacology*. 2011;36:1219–1226.
16. McGuire P, Robson P, Cubala WJ, et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. *Am J Psychiatry*. 2018;175:225–231.
17. Leweke FM, Piomelli D, Pahlisch F, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. *Translational Psychiatry*. 2012;2:e94.
18. Crippa JAS, Hallak JEC, Zuardi AW, et al. Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms? *Eur Arch Psychiatry Clin Neurosci*. 2019;269:121–133.
19. Couch DG, Maudslay H, Doleman B, et al. The use of cannabinoids in colitis: a systematic review and meta-analysis. *Inflamm Bowel Dis*. 2018;24:680–697.
20. Turna J, Syan SK, Frey BN, et al. Cannabidiol as a novel candidate alcohol use disorder pharmacotherapy: a systematic review. *Alcohol Clin Exp Res*. 2019;43:550–563.
21. Urits I, Borchart M, Hasegawa M, et al. An update of current cannabis-based pharmaceuticals in pain medicine. *Pain Ther*. 2019;8:41–51.
22. Noreen N, Muhammad F, Akhtar B, et al. Is cannabidiol a promising substance for new drug development? A review of its potential therapeutic applications. *Crit Rev Eukaryot Gene Expr*. 2018;28:73–86.
23. Morales P, Hurst DP, Reggio PH. Molecular targets of the phytocannabinoids: a complex picture. *Prog Chem Org Nat Prod*. 2017;103:103–131.
24. Ibeas Bih C, Chen T, Nunn AV, et al. Molecular targets of cannabidiol in neurological disorders. *Neurotherapeutics*. 2015;12:699–730.
25. Papagianni EP, Stevenson CW. Cannabinoid regulation of fear and anxiety: an update. *Curr Psychiatry Rep*. 2019;21:38.
26. Campos AC, Guimarães FS. Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. *Psychopharmacology (Berl)*. 2008;199:223–230.
27. De Petrocellis L, Ligresti A, Moriello AS, et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. *Br J Pharmacol*. 2011;163:1479–1494.
28. Crippa JA, Derenusson GN, Ferrari TB, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. *J Psychopharmacol*. 2011;25:121–130.
29. Bisogno T, Hanuš L, De Petrocellis L, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. *Br J Pharmacol*. 2001;134:845–852.
30. Patel S, Hillard CJ. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. *J Pharmacol Exp Ther*. 2006;318:304–311.
31. Hasin DS, Sarvet AL, Cerdá M, et al. US adult illicit cannabis use, cannabis use disorder, and medical marijuana laws: 1991–1992 to 2012–2013. *JAMA Psychiatry*. 2017;74:579–588.
32. Martins SS, Mauro CM, Santaella-Tenorio J, et al. State-level medical marijuana laws, marijuana use and perceived availability of marijuana among the general U.S. population. *Drug Alcohol Depend*. 2016;169:26–32.
33. Wen H, Hockenberry JM, Cummings JR. The effect of medical marijuana laws on adolescent and adult use of marijuana, alcohol, and other substances. *J Health Econ*. 2015;42:64–80.
34. Iffland K, Grotenhermen F. An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. *Cannabis Cannabinoid Res*. 2017;2:139–154.
35. World Health Organization (WHO). Cannabidiol (CBD) Critical Review Report. Geneva, Switzerland: WHO, 2018.
36. Fasinu PS, Phillips S, ElSohly MA, et al. Current status and prospects for cannabidiol preparations as new therapeutic agents. *Pharmacotherapy*. 2016;36:781–796.
37. Bergamaschi MM, Queiroz RH, Zuardi AW, et al. Safety and side effects of cannabidiol, a *Cannabis sativa* constituent. *Curr Drug Saf*. 2011;6:237–249.
38. World Health Organization (WHO). Fortieth Report. Geneva, Switzerland: WHO, 2018.
39. Hindocha C, Freeman TP, Schafer G, et al. Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users. *Eur Neuropsychopharmacol*. 2015;25:325–334.
40. Babalonis S, Haney M, Malcolm RJ, et al. Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. *Drug Alcohol Depend*. 2017;172:9–13.
41. Schoedel KA, Szeto I, Setnik B, et al. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: a randomized, double-blind, controlled trial. *Epilepsy Behav*. 2018;88:162–171.
42. Haney M, Malcolm RJ, Babalonis S, et al. Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked cannabis. *Neuropsychopharmacology*. 2016;41:1974–1982.
43. Solowij N, Broyd S, Greenwood LM, et al. A randomised controlled trial of vaperised delta(9)-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects. *Eur Arch Psychiatry Clin Neurosci*. 2019;269:17–35.
44. Guimarães FS, Chiaretti TM, Graeff FG, et al. Antianxiety effect of cannabidiol in the elevated plus-maze. *Psychopharmacology (Berl)*. 1990;100:558–559.
45. Onaivi ES, Green MR, Martin BR. Pharmacological characterization of cannabinoids in the elevated plus maze. *J Pharmacol Exp Ther*. 1990;253:1002–1009.
46. Zuardi AW, Shirakawa I, Finkelfarb E, et al. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. *Psychopharmacology (Berl)*. 1982;76:245–250.
47. Karniol IG, Shirakawa I, Kasinski N, et al. Cannabidiol interferes with the effects of delta 9-tetrahydrocannabinol in man. *Eur J Pharmacol*. 1974;28:172–177.
48. Crippa JA, Zuardi AW, Garrido GE, et al. Effects of cannabidiol (CBD) on regional cerebral blood flow. *Neuropsychopharmacology*. 2004;29:417–426.
49. Fusar-Poli P, Crippa JA, Bhattacharyya S, et al. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. *Arch Gen Psychiatry*. 2009;66:95–105.
50. Linares IM, Zuardi AW, Pereira LC, et al. Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. *Braz J Psychiatry*. 2019;41:9–14.
51. Borgwardt SJ, Allen P, Bhattacharyya S, et al. Neural basis of Delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. *Biol Psychiatry*. 2008;64:966–973.
52. Fusar-Poli P, Allen P, Bhattacharyya S, et al. Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol. *Int J Neuropsychopharmacol*. 2010;13:421–432.
53. Soares VP, Campos AC. Evidences for the anti-panic actions of cannabidiol. *Curr Neuropharmacol*. 2017;15:291–299.
54. Elms L, Shannon S, Hughes S, et al. Cannabidiol in the treatment of post-traumatic stress disorder: a case series. *J Altern Complement Med*. 2019;25:392–397.
55. Shannon S, Lewis N, Lee H, et al. Cannabidiol in anxiety and sleep: a large case series. *Perm J*. 2019;23:18–041.
56. Shannon S, Opila-Lehman J. Effectiveness of cannabidiol oil for pediatric anxiety and insomnia as part of posttraumatic stress disorder: a case report. *Perm J*. 2016;20:16-005.
57. van der Flier FE, Kwee CMB, Cath DC, et al. Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias: study protocol of a randomized controlled trial. *BMC Psychiatry*. 2019;19:69.
58. Ameringen MV. Cannabidiol for the treatment of anxiety disorders: an 8-week pilot study. *ClinicalTrials.gov*. NCT03549819. Published 2019. Accessed 2019.

59. Gruber. Sublingual cannabidiol for anxiety. ClinicalTrials.gov. NCT02548559. Published 2018. Accessed 2018.
60. Khoury JM, Neves MCLD, Roque MAV, et al. Is there a role for cannabidiol in psychiatry? *World J Biol Psychiatry*. 2019;20:101–116.
61. Altemus M, Sarvaiya N, Neill Epperson C. Sex differences in anxiety and depression clinical perspectives. *Front Neuroendocrinol*. 2014;35:320–330.
62. Donner NC, Lowry CA. Sex differences in anxiety and emotional behavior. *Pflugers Arch*. 2013;465:601–626.
63. Green T, Flash S, Reiss AL. Sex differences in psychiatric disorders: what we can learn from sex chromosome aneuploidies. *Neuropsychopharmacology*. 2019;44:9–21.
64. Li SH, Graham BM. Why are women so vulnerable to anxiety, trauma-related and stress-related disorders? The potential role of sex hormones. *Lancet Psychiatry*. 2017;4:73–82.
65. McLean CP, Asnaani A, Litz BT, et al. Gender differences in anxiety disorders: prevalence, course of illness, comorbidity and burden of illness. *J Psychiatr Res*. 2011;45:1027–1035.
66. Vesga-Lopez O, Schneier FR, Wang S, et al. Gender differences in generalized anxiety disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). *J Clin Psychiatry*. 2008;69:1606–1616.
67. Jalnapurkar I, Allen M, Pigott T. Sex differences in anxiety disorders: a review. *J Psychiatry Depress Anxiety*. 2018;4:12.
68. Pigott TA. Anxiety disorders in women. *Psychiatr Clin North Am*. 2003;26:621–672, vi–vii.
69. Pigott TA. Gender differences in the epidemiology and treatment of anxiety disorders. *J Clin Psychiatry*. 1999;60(Suppl. 18):4–15.
70. Cooper ZD, Craft RM. Sex-dependent effects of cannabis and cannabinoids: a translational perspective. *Neuropsychopharmacology*. 2018;43:34–51.
71. Nadulski T, Pragst F, Weinberg G, et al. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC versus standardized cannabis extract. *Ther Drug Monit*. 2005;27:799–810.
72. Klumpers LE, Cole DM, Khalili-Mahani N, et al. Manipulating brain connectivity with delta(9)-tetrahydrocannabinol: a pharmacological resting state fMRI study. *Neuroimage*. 2012;63:1701–1711.
73. Spindle TR, Cone EJ, Schlienz NJ, et al. Acute pharmacokinetic profile of smoked and vaporized cannabis in human blood and oral fluid. *J Anal Toxicol*. 2019;43:233–258.
74. Matheson JMSB, Di Ciano P, Fares A, et al. Sex differences in the acute effects of smoked cannabis: evidence from a human laboratory study of young adults. *Psychopharmacology*. 2019; DOI: 10.1007/s00213-019-05369-y.
75. Onaivi ES, Chaudhuri G, Abaci AS, et al. Expression of cannabinoid receptors and their gene transcripts in human blood cells. *Progress Neuropsychopharmacol Biol Psychiatry*. 1999;23:1063–1077.
76. Normandin MD, Zheng MQ, Lin KS, et al. Imaging the cannabinoid CB1 receptor in humans with [¹¹C]OMAR: assessment of kinetic analysis methods, test-retest reproducibility, and gender differences. *J Cereb Blood Flow Metab*. 2015;35:1313–1322.
77. Neumeister A, Normandin MD, Pietrzak RH, et al. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. *Mol Psychiatry*. 2013;18:1034–1040.
78. Van Laere K, Goffin K, Casteels C, et al. Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [(18)F]MK-9470 PET. *Neuroimage*. 2008;39:1533–1541.
79. Cooper ZD, Haney M. Investigation of sex-dependent effects of cannabis in daily cannabis smokers. *Drug Alcohol Depend*. 2014;136:85–91.
80. Wardle MC, Marcus BA, de Wit H. A preliminary investigation of individual differences in subjective responses to D-amphetamine, alcohol, and delta-9-tetrahydrocannabinol using a within-subjects randomized trial. *PLoS One*. 2015;10:e0140501.
81. Fogel JS, Kelly TH, Westgate PM, et al. Sex differences in the subjective effects of oral delta(9)-THC in cannabis users. *Pharmacol Biochem Behav*. 2017;152:44–51.
82. Roser PGJ, Weinberg G, Juckel G, et al. Psychomotor performance in relation to acute oral administration of Delta9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects. *Eur Arch Psychiatry Clin Neurosci*. 2009;284–292.
83. Wiers CE, Shokri-Kojori E, Wong CT, et al. Cannabis abusers show hypofrontality and blunted brain responses to a stimulant challenge in females but not in males. *Neuropsychopharmacology*. 2016;41:2596–2605.
84. Khan SS, Secades-Villa R, Okuda M, et al. Gender differences in cannabis use disorders: results from the National Epidemiologic Survey of Alcohol and Related Conditions. *Drug Alcohol Depend*. 2013;130:101–108.
85. Cuttler C, Mischley LK, Sexton M. Sex differences in cannabis use and effects: a cross-sectional survey of cannabis users. *Cannabis Cannabinoid Res*. 2016;1:166–175.
86. Herrmann ES, Weerts EM, Vandrey R. Sex differences in cannabis withdrawal symptoms among treatment-seeking cannabis users. *Exp Clin Psychopharmacol*. 2015;23:415–421.
87. Millar SA, Stone NL, Yates AS, et al. A systematic review on the pharmacokinetics of cannabidiol in humans. *Front Pharmacol*. 2018;9:1365.

Cite this article as: Wright M, Di Ciano P, Brands B (2019) Use of cannabidiol for the treatment of anxiety: a short synthesis of pre-clinical and clinical evidence. *Cannabis and Cannabinoid Research* 5:3, 191–196, DOI: 10.1089/can.2019.0052.

Abbreviations Used

5-HT1A = 5-hydroxytryptamine 1A
 CB1 = cannabinoid type 1
 CBD = cannabidiol
 EPM = elevated plus-maze
 FAAH = fatty acid amide hydrolase
 GAD = generalized anxiety disorder
 OCD = obsessive-compulsive disorder
 PTSD = post-traumatic stress disorder
 SAD = social anxiety disorder
 THC = Δ-9-tetrahydrocannabinol
 TRPV1 = transient receptor potential, vanilloid type 1 receptor